Nucleoside diphosphate kinase B promotes osteosarcoma proliferation through c-Myc

Cancer Biol Ther. 2018 Jul 3;19(7):565-572. doi: 10.1080/15384047.2017.1416273. Epub 2018 Apr 13.

Abstract

Osteosarcoma (OS) is one of the most common primary bone tumors and has a high disablity rate and case-fatality rate. The protracted stagnancy of the chemotherapy program and surgical technology for OS treatment prompted us to focus on the mechanisms of cancer carcinogenesis progression in OS. Nucleoside diphosphate kinase B (NME2) is a type of nucleoside diphosphate kinase that plays an important role in cellular processes. In this study, we report overexpression of NME2 in OS cell lines and correlate this overexpression with the clinicopathologic features of osteosarcoma. We used si-NME2 to downregulate expression of NME2 in OS cell lines. The results of the CCK8 and clone forming assays show that NME2 promotes OS cell line proliferation. Western blot assays show that deregulation of NME2 results in enhanced the expression of c-Myc, which promotes OS proliferation.

Keywords: NME2; c-Myc; gene; osteosarcoma; proliferation.

MeSH terms

  • Adult
  • Bone Neoplasms / pathology*
  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation
  • Down-Regulation
  • Female
  • G2 Phase Cell Cycle Checkpoints
  • Humans
  • Male
  • NM23 Nucleoside Diphosphate Kinases / genetics
  • NM23 Nucleoside Diphosphate Kinases / metabolism*
  • Osteosarcoma / pathology*
  • Proto-Oncogene Proteins c-myc / metabolism*
  • Proto-Oncogenes
  • RNA, Small Interfering / metabolism
  • Up-Regulation
  • Young Adult

Substances

  • MYC protein, human
  • NM23 Nucleoside Diphosphate Kinases
  • Proto-Oncogene Proteins c-myc
  • RNA, Small Interfering
  • NME2 protein, human